CARSGEN THERAPEUTICS HOLDINGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.5 HKD | 0.00% |
|
-21.33% | -30.77% |
| Apr. 12 | Carsgen Therapeutics To Give Cancer Drug Oral Presentation at ASCO 2024 | MT |
| Mar. 26 | CARsgen Therapeutics Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
CARsgen Therapeutics Holdings Ltd is a China-based investment holding company principally engaged in discovering, developing and commercializing innovative chimeric antigen receptor (CAR)-T cell therapies. The Company's therapies are applied in the treatment of hematological malignancies and solid tumors. The Company have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The Company conducts its businesses in China and the United States.
Calendar
2024-08-19
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
4.159
CNY
Average target price
7.954
CNY
Spread / Average Target
+91.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -30.77% | 331M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.78% | 21.66B | |
| -18.35% | 20.77B | |
| -8.65% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- 2171 Stock
- News CARsgen Therapeutics Holdings Limited
- CARsgen Therapeutics : to be Added to Hang Seng Composite Index; Shares Rise 3%
